Feature | January 14, 2013

Oslo Breast Cancer Screening Trial Concludes Use of 3-D With 2-D Exam Finds Significantly More Cancers

Hologic Inc. Radiology RSNA 3-D Mammography Clinical Study

January 14, 2013 — Hologic Inc. announced that a groundbreaking new clinical study published in Radiology, the Radiological Society of North America scientific journal, found that the addition of three dimensional (3-D) mammography (breast tomosynthesis) screening technology to a 2-D breast screening exam significantly increased cancer detection while reducing the number of false positives.

The study, "Comparison of Digital Mammography Alone and Digital Mammography plus Tomosynthesis in a Population-based Screening Program," was led by Per Skaane, M.D., Ph.D. of Oslo University Hospital Ullevaal. The study was based on 12,631 screening examinations in a large hospital in Norway.

The researchers using Hologic's 3-D mammography technology in combination with a 2-D mammogram found a significant increase in cancer detection rates, particularly for invasive cancers, and a simultaneous decrease in false-positive rates compared with 2-D mammography alone. Significant findings include:

  • A 40 percent increase in the detection of invasive breast cancers
  • A 27 percent increase in the detection of all cancers (invasive and in situ cancers combined)
  • A 15 percent decrease in false-positive rates

The authors reported that the increase in cancer detection was found across all breast tissue densities, from dense to fatty. At the same time, there was no increase in the detection of ductal carcinoma in situ (DCIS), which is non-invasive and cited by critics of mammography screening as potentially being over-diagnosed.

As a result of the large increase in the detection of invasive cancers rather than in situ cancers the authors of the paper state, "Perhaps our most important observation is that with the mammography-plus-tomosynthesis arm, the actual benefit, in terms of possibly improving outcome owing to earlier detection, may be larger than merely the difference in the total count or number of detected cancers."

Rob Cascella, Hologic's president and chief executive iofficer said, "A number of major papers demonstrating the value of 3-D mammography have been published in the last few months. The Oslo trial is the first large-scale prospective study to show the additional cancers found with 3-D mammography in combination with 2-D mammography were invasive cancers — the very type of cancers we want to detect and treat early. Three-dimensional mammography is the best breast screening technology to date in that it finds significantly more invasive cancers while also reducing false positives. Most other imaging technologies for screening require users to compromise specificity (recall rate) for sensitivity (cancer detection). We believe the value of 3-D mammography in breast cancer screening is most compelling."

Three-dimensional mammography was approved for clinical use for breast cancer screening and diagnosis in the United States in February 2011 and has been available in countries recognizing the CE mark since 2008. Hologic's 3-D mammography technology is in use in 47 states and 30 countries outside the United States. Unlike a screening 2-D digital mammogram, which involves a single X-ray image of the breast, 3-D mammography captures multiple, low-dose images from multiple angles around the breast. The images are then used to produce a 3-D reconstruction of the breast.

Skaane and his research team in Oslo are well known for their research. Their Oslo I and Oslo II trials were important studies comparing 2-D digital mammography to screen-film for the detection of breast cancer.

The study was published online in advance of print on the Radiology website.

For more information: www.hologic.com/investors-overview

Related Content

Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
Warm Springs Health & Wellness Center Implements Digisonics Solution for OB Ultrasound
News | Ultrasound Women's Health | June 17, 2019
Warm Springs Health & Wellness Center in Warm Springs, Ore., has selected the Digisonics OB PACS (picture archiving...
Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

News | Mammography | June 14, 2019
Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused...
Ikonopedia Showcases Risk Assessment and Resolution Manager Tools at SIIM and AHRA
News | Mammography Reporting Software | June 13, 2019
Ikonopedia will showcase its suite of structured breast reporting and Mammography Quality Standards Act (MQSA)...
iCAD Introduces ProFound AI for 2D Mammography in Europe
News | Artificial Intelligence | June 13, 2019
iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to...
Three Palm Software Releases WorkstationOne Version 1.8.8
Technology | Mammography Reporting Software | June 12, 2019
Three Palm Software announced the release of the 1.8.8 version of its breast imaging workstation, WorkstationOne. This...
Volpara Health Technologies to Acquire MRS Systems Inc.
News | Mammography Reporting Software | June 04, 2019
Volpara Health Technologies, Volpara Solutions' parent company, has signed a binding agreement to acquire U.S.-based...